TLX 11-DAY DEADLINE ALERT: Hagens Berman Urges Telix (TLX) Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain
12/29/2025 04:48 PM • Hagens Berman is urging Telix Pharmaceuticals investors to act by January 9, 2026, as lead plaintiff deadline approaches in a securities class action lawsuit. The lawsuit alleges the company materially overstated therapeutic candidate progress and concealed supply chain/manufacturing deficiencies. Regulatory setbacks include an SEC subpoena regarding drug development disclosures and an FDA Complete Response Letter rejecting the Zircaix application due to Chemistry, Manufacturing, and Controls deficiencies, triggering a 21% stock decline.
TLX - Company faces dual regulatory investigations (SEC subpoena and FDA CRL), alleged material misstatements about drug development progress, concealed supply chain deficiencies, and significant stock decline (21% drop), resulting in securities fraud litigation and investor losses.
Investing.com • Itai Smidt